The researchers excluded patients already taking an angiotensin-receptor blocker
or angiotensin-converting enzyme inhibitor.
Effects of the angiotensin-receptor blocker
telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
proteinuria or symptomatic left ventricular systolic dysfunction despite treatment with and ACE inhibitor or an angiotensin-receptor blocker
alone," said Dr.
A randomized trial of the angiotensin-receptor blocker
valsartan in chronic heart failure.
ACE = angiotensin-converting enzyme; ARB = angiotensin-receptor blocker
For example, 92 per cent of Kaiser Permanente patients with ACS were discharged with an ACE inhibitor(3) or angiotensin-receptor blocker
(ARB)(4), recommended in the guidelines as an effective therapy for reducing mortality from heart attacks.
The FDA's Cardiovascular and Renal Drugs Advisory Committee voted unanimously against approving the angiotensin-receptor blocker
for reducing the risk of MI, stroke, cardiovascular deaths, or hospitalization for heart failure in patients 55 years or older at high risk of developing major cardiovascular events.
To start treatment according to the algorithm, which called for a low dose (half tablet) of a marketed formulation that combined a diuretic with either an angiotensin-converting enzyme inhibitor or an angiotensin-receptor blocker
, physicians could choose among 11 formulations that were on the Canadian market at the time the study began.
Aliskiren failed to produce additional blood pressure lowering when it was added to an angiotensin-receptor blocker
Treatment of heart failure typically begins with an ACE inhibitor or an angiotensin-receptor blocker
, mainly for historic reasons: ACE inhibitors were proven effective for treating heart failure first.
Most patients were also treated with an ACE inhibitor or an angiotensin-receptor blocker
, and most were also treated with a diuretic.
The 15,245-patient study, designed to show the efficacy of the angiotensin-receptor blocker
valsartan, confirmed the value of calcium channel blockers (CCBs) by showing that both drugs reduced blood pressure (mean reduction of 17.